Research trends on platelet-rich plasma in improving ovarian dysfunction: A bibliometric and visualization analysis
Liu F., Li J., Li J., Lan M., Wang X., Zhang S.
Laboratory Study, published in Regen Ther (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Regen Ther (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41079455
- PMCID
- PMC12514542
- DOI
- 10.1016/j.reth.2025.09.010
Abstract (original English)
Introduction Platelet-rich plasma (PRP) has attracted attention due to its potential to restore or enhance ovarian function. However, resources for evaluating the research trends of PRP in improving ovarian dysfunction are limited. This study aims to conduct a bibliometric analysis of the relevant literature on PRP improving ovarian dysfunction, and explore the current research status, hotspots and frontiers in this field. Methods Studies on PRP improving ovarian dysfunction were retrieved from the Science Citation Index Extended (SCI-E) database of Web of Science (WOS). The research trends and characteristics were analyzed using visualization software such as VOSviewer, SCImago Graphica and CiteSpace. Results A total of 193 studies were identified. The USA, IRAN and CHINA were the most productive countries. The number of publications on PRP improving ovarian dysfunction has shown a significant upward trend since 2018. Papers published in the United States lead in terms of the number of publications, citation counts and H-index. Although the number of publications in Turkey is slightly lower than that in China, its H-index and average citations are higher than those in China. The strongest keyword is "stimulation", and the keyword with the longest duration of an outbreak is "gonadotropins" (starting in 2010 and ending in 2018). The 5 largest co-citation clusters are as follows:
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.